Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

primary analysis comparing the 900-mcg albinterferon alfa-2b treatment group to the peginterferon alfa-2a treatment group.

  • Based on an ITT analysis of results for the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, 47.3% (208/440) of patients in this treatment group achieved SVR, vs. 51.0% (225/441) in the peginterferon alfa-2a treatment group, which statistically demonstrated non-inferiority (95% CI -9.4%, 3.2%, p=0.0029, adjusted for baseline stratification factors).
  • The incidence of serious and/or severe adverse events was 28.3% (124/440) in the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, vs. 23.1% (102/441) in the peginterferon alfa-2a treatment group.
  • The incidence of serious and/or severe pulmonary adverse events included the following: serious and/or severe pulmonary infections were 3.2% (14/440) for 1200-mcg albinterferon alfa-2b, vs. 1.1% (5/441) for peginterferon alfa-2a; and serious and/or severe respiratory, thoracic or mediastinal disorders were 3.0% (13/440) for 1200-mcg albinterferon alfa-2b, vs. 0.5% (2/441) for peginterferon alfa-2a.
  • Overall, adverse events observed were those typically expected with interferon therapy. The incidence of discontinuations due to adverse events was 10.0% (44/440) in the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, vs. 4.1% (18/441) in the peginterferon alfa-2a treatment group.

Additional Safety Data of Interest from the Phase 3 Clinical Trials of Albinterferon Alfa-2b Versus Peginterferon Alfa-2a

HGS has conducted two randomized active-controlled Phase 3 clinical trials of albinterferon alfa-2b versus peginterferon alfa-2a - ACHIEVE 1 in genotype 1 chronic hepatitis C, and ACHIEVE 2/3 in genotypes 2 and 3 chronic hepatitis C.
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 DePuy Synthes CMF* today announced ... first commercially available biosynthesized dural replacement derived from cellulose ... part of the DePuy Synthes Companies of Johnson & ... that covers and protects the brain and spinal cord. ... surgeons to access the brain. A dural graft, which ...
(Date:5/4/2015)... , May 4, 2015 Former NASA ... News online last week where he discussed Theradome™, the ... be FDA-cleared. The FOX segment shows firsthand how, via ... affordable hair loss solution that will not require surgery ... the mitochondria at the base of the hair follicle, ...
(Date:5/4/2015)... and TORONTO , May 4, ... (OTCQB:GNBT) today announced that it intends to dividend to ... upon completion of a definitive licensing agreement to license ... ( www.smoofi.com ) (OTCQB:SMFI). As announced on ... of intent in respect of the licensing of its ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
(Date:5/4/2015)... 2015 In May of 2010, after two ... life. In the wake of this tragedy, Ty’s parents Kirk ... that exposes the grim reality of bullying and its devastating ... Kirk and Laura to share their story and offer education ... to another family — a mission that took the Smalley ...
(Date:5/4/2015)... Now in its seventh year, the ... have made outstanding contributions to the company, to their ... acute and post-acute care settings. The five award categories ... the Year, Advanced Practice Clinician of the Year, Newcomer ... Year. Recipients are selected by IPC’s senior management team. ...
(Date:5/4/2015)... City, OK and Seattle, WA (PRWEB) May 04, 2015 ... announced the formation of a collaboration to facilitate development ... number of ophthalmic disorders that lead to blindness, including ... to the MiDROPS™ formulation platform developed by EyeCRO, which ... the eye via a topical eyedrop. , Under ...
(Date:5/4/2015)... SC (PRWEB) May 04, 2015 Ticket Down ... at the Colonial Life Arena in Columbia, South Carolina. ... the continuation of his “Out There” tour which originally kicked ... long tour is North America and the legendary performer recently ... at the Wells Fargo Arena on June 21st, in Charlottesville, ...
(Date:5/4/2015)... 2015 Pricing Healthcare announces it ... one patient receiving care at St. George Surgical Center ... must be performed by July 15th, 2015, and the patient ... up front and forego the filing of insurance claims). , ... every year, and it devastates more and more individuals and ...
Breaking Medicine News(10 mins):Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3
... code for a type of pancreatic cancer, called neuroendocrine or ... 20 issue of Science Express, shows that patients ... as those without them. "One of the most significant ... of rare cancer has a unique genetic code that predicts ...
... Researchers from Upstate New York institutions, including the ... two industrial pollutants in carp in eastern Lake ... demonstrating the lasting environmental effects of human activity ... The two contaminants the scientists studied were polychlorinated ...
... in an 8-week mindfulness meditation program appears to make ... of self, empathy and stress. In a study ... Psychiatry Research: Neuroimaging, a team led by ... their study, the first to document meditation-produced changes over ...
... , FRIDAY, Jan. 21 (HealthDay News) -- Americans suffering from ... in a cream to help soothe their aches. But ... on: analgesics delivered through a medicated patch placed directly where ... the country,s first over-the-counter, pain-relieving transdermal patches in 2008. But ...
... Department of Psychiatry at Case Western Reserve University School of ... National Institute of Mental Health (NIMH) for the long-term study ... the NIMH, one of the National Institutes of Health (NIH), ... in which 707 children between the ages of six and ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay News) -- ... think vaccines don,t cause autism, a new Harris Interactive/HealthDay ... vaccines, like the measles-mumps-rubella (MMR) vaccine, can cause the disorder, ... conducted last week, following news reports that said the lead ...
Cached Medicine News:Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 2Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 3Health News:Scientists find industrial pollutants in Eastern Lake Erie carp 2Health News:Scientists find industrial pollutants in Eastern Lake Erie carp 3Health News:Mindfulness meditation training changes brain structure in 8 weeks 2Health News:Mindfulness meditation training changes brain structure in 8 weeks 3Health News:Pain Patches Making Gains in U.S. 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 2Health News:Case Western Reserve receives $7.8M to study manic symptoms in children 3Health News:Nearly Half of Americans Still Suspect Vaccine-Autism Link 2Health News:Nearly Half of Americans Still Suspect Vaccine-Autism Link 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... Linear high frequency ... breast and superficial ... exclusive Hemispheric Sound ... technologies. This multi-frequency ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: